CN112105617B - 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 - Google Patents

一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN112105617B
CN112105617B CN201980023228.3A CN201980023228A CN112105617B CN 112105617 B CN112105617 B CN 112105617B CN 201980023228 A CN201980023228 A CN 201980023228A CN 112105617 B CN112105617 B CN 112105617B
Authority
CN
China
Prior art keywords
compound
crystal form
reaction
added
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980023228.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112105617A (zh
Inventor
陈新海
于衍新
陈鑫德
张丽
陈兆国
谢程
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingnuohu Pharmaceutical Hangzhou Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN112105617A publication Critical patent/CN112105617A/zh
Application granted granted Critical
Publication of CN112105617B publication Critical patent/CN112105617B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980023228.3A 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 Active CN112105617B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103998766 2018-04-28
CN201810399876 2018-04-28
PCT/CN2019/084822 WO2019206336A1 (zh) 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN112105617A CN112105617A (zh) 2020-12-18
CN112105617B true CN112105617B (zh) 2022-04-05

Family

ID=68294924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023228.3A Active CN112105617B (zh) 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Country Status (9)

Country Link
US (1) US11649239B2 (https=)
EP (1) EP3766884B1 (https=)
JP (1) JP7406691B2 (https=)
CN (1) CN112105617B (https=)
DK (1) DK3766884T3 (https=)
ES (1) ES2908424T3 (https=)
PL (1) PL3766884T3 (https=)
PT (1) PT3766884T (https=)
WO (1) WO2019206336A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3766884T3 (pl) * 2018-04-28 2022-07-18 Medshine Discovery Inc. Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
PE20230372A1 (es) * 2019-08-26 2023-03-06 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976753A1 (en) * 1997-03-24 2000-02-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
CN1596258A (zh) * 2001-11-30 2005-03-16 先灵公司 腺A2α受体拮抗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
PL3766884T3 (pl) * 2018-04-28 2022-07-18 Medshine Discovery Inc. Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976753A1 (en) * 1997-03-24 2000-02-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
CN1596258A (zh) * 2001-11-30 2005-03-16 先灵公司 腺A2α受体拮抗剂

Also Published As

Publication number Publication date
US11649239B2 (en) 2023-05-16
EP3766884B1 (en) 2022-02-09
ES2908424T3 (es) 2022-04-29
PT3766884T (pt) 2022-03-31
CN112105617A (zh) 2020-12-18
DK3766884T3 (da) 2022-03-28
EP3766884A4 (en) 2021-03-31
PL3766884T3 (pl) 2022-07-18
WO2019206336A1 (zh) 2019-10-31
JP2021522335A (ja) 2021-08-30
JP7406691B2 (ja) 2023-12-28
US20210094957A1 (en) 2021-04-01
EP3766884A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
CN112105617B (zh) 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法
CN119039237B (zh) 一种喹唑啉胺化合物及其制备方法与应用
US8993612B2 (en) Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CN116528868A (zh) 三环kras g12c抑制剂
CN111566102B (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
JPH11504922A (ja) 蛋白チロシンキナーゼ媒介細胞増殖を抑制するためのピリド［２，３−ｄ］ピリミジン類
CN107973783A (zh) 作为erk抑制剂的苯胺嘧啶衍生物
EP3686199B9 (en) Fused ring derivative as a2a receptor inhibitor
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CA3008689A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN114539226A (zh) 一种含吲哚类衍生物自由碱的晶型及其制备方法和应用
CN117800953A (zh) 一种2-芳香胺基嘧啶类化合物及其制备方法与应用
CN104418867B (zh) 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
HK40040486A (en) Crystal form and salt type of triazolopyrimidine compound and preparation method therefor
CN113527306B (zh) 喹啉类TGF-β1抑制剂的晶型
HK40040486B (zh) 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法
CN116685588B (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用
JP2023543281A (ja) アリールアミノキナゾリン含有化合物の塩、およびその製造方法と使用
CN117126164B (zh) 一种吡咯并三嗪类化合物，其制备方法及用途
CN113891749A (zh) 喹啉衍生物及其用于治疗癌症的用途
CN113527305B (zh) 喹啉类TGF-β1抑制剂的可药用盐及其制备方法
CN115197203B (zh) 苯胺嘧啶类化合物、其制备方法及应用
KR20240049314A (ko) 피리미딘 유도체 및 이의 약학적으로 허용 가능한 염의 다결정체 및 응용
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040486

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231130

Address after: No. 291 Fucheng Road, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province, China, and 1-1210, Heda Pharmaceutical Valley Center

Patentee after: Yingnuohu Pharmaceutical (Hangzhou) Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.